Thus, more recent trials are evaluating mTOR inhibition with everolimus in the adjuvant setting in high-risk estrogen receptor-positive, HER2-negative early breast cancer (BOLERO-2) [13,14] or in trastuzumab resistant, HER-2 positive, advanced breast cancer patients (BOLERO-3) [15]. Here, ESR1 is linked to breast carcinoma.